GlobeNewswire·Nov 4, 2026, 8:30 AM ET

Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015

Tango Therapeutics & Erasca announced that enrollment is now open for a Phase 1/2 study of vopimetostat combined with ERAS-0015 in patients with MTAP-deleted pancreatic ductal adenocarcinoma (PDAC) or MTAP-deleted/RAS-mutant non-small cell lung cancer (NSCLC).
The open-label, multicenter trial aims to determine the maximum tolerated dose of the combination regimen while assessing antitumor activity, pharmacokinetics, safety, & tolerability.
Vopimetostat is an investigational oral PRMT5 inhibitor that has demonstrated favorable safety & durable activity in MTAP-deleted cancers in prior studies.
ERAS-0015 is an oral pan-RAS molecular glue designed to inhibit RAS signaling with high potency & the potential to prevent resistance against mutant-selective inhibitors.
Preclinical data indicates ERAS-0015 shows approximately 8-21 times higher binding affinity to cyclophilin A compared to RMC-6236 & achieves comparable tumor growth inhibition at doses one-tenth to one-fifth the strength of RMC-6236.
The study is registered on clinicaltrials.gov under identifier NCT07897734.
Both companies highlighted the synergistic potential of co-targeting PRMT5 & RAS to achieve deeper, more durable responses in difficult-to-treat cancers.